Trial Profile
Safety and Efficacy Study of ESBA1008 Versus LUCENTIS for the Treatment of Exudative Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Jul 2017
Price :
$35
*
At a glance
- Drugs Brolucizumab (Primary) ; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus First in man; Proof of concept; Therapeutic Use
- Sponsors Alcon
- 04 Nov 2014 New trial record